

**Supplementary Table 6.** Comparison of baseline characteristics of ElastQ-ACLD FN vs. ElastQ-ACLD TN

	ElastQ-ACLD FN (n=32)	ElastQ-ACLD TN (n=323)	P-value
Sex			
Female	17 (53.1)	151 (46.7)	0.615
Male	15 (46.9)	172 (53.3)	
Age (year), median (IQR)	61.0 (13.5)	54.0 (23.5)	0.006
BMI (m/kg <sup>2</sup> ), median (IQR)	28.0 (8.9)	25.1 (5.8)	0.008
Etiology			
ALD	6 (18.8)	15 (4.6)	<0.001
Viral Hepatitis	14 (43.8)	219 (67.8)	
NAFLD	5 (15.6)	67 (20.7)	
Cholestatic/AIH	2 (6.3)	5 (1.5)	
Other/Cryptogenic	5 (15.6)	17 (5.3)	
AST (U/L), median (IQR)	59 (37)	25 (18)	<0.001
ALT (U/L), median (IQR)	47 (38)	28 (25)	<0.001
GGT (U/L), median (IQR)	61 (129)	27 (42)	<0.001
FIB 4, median (IQR)	3.61 (6.00)	1.24 (0.92)	<0.001
Platelet (g/L), median (IQR)	133 (93)	215 (76)	<0.001
Albumin (g/dL), median (IQR)	33.3 (9.9)	45.0 (4.4)	<0.001
INR, median (IQR)	1.30 (0.43)	1.0 (0.19)	<0.001
Bilirubin (mg/dL), median (IQR)	1.29 (1.25)	0.60 (0.49)	<0.001
VCTE-LSM median (kPa), median (IQR)	18.6 (17.3)	5.10 (1.80)	<0.001
VCTE-LSM IQR/Med. (%), median (IQR)	18.5 (9.5)	13.0 (9.5)	<0.001
ElastQ-LSM median (kPa), median (IQR)	5.3 (0.8)	5.2 (1.0)	0.669
ElastQ-LSM IQR/Med. (%), median (IQR)	17.0 (14.3)	9.7 (10.6)	0.003

Values are presented as number (%) unless otherwise indicated.

ACLD, advanced chronic liver disease; FN, false-negative; TN, true-negative; IQR, interquartile range; BMI, body mass index; ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LSM, liver stiffness measurement; GGT, gamma-glutamyl transferase; FIB 4, Fibrosis-4 score; INR international normalized ratio; VCTE, vibration-controlled transient elastography; LSM, liver stiffness measurement; Med., median.